Merck & Co. (MRK)
(Delayed Data from NYSE)
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval
by Zacks Equity Research
Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.
Merck Closes Acquisition of Controlling Stake in Vallee S.A
by Zacks Equity Research
Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
by Arpita Dutt
Gilead's (GILD) valuation looks compelling but is the company really poised for
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
by Zacks Equity Research
Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.
Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
by Zacks Equity Research
Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.
Stock Market Roundup, March 7: SNAP Falls Again, Drug Stocks Dip
by Ryan McQueeney
Stocks opened in the red and were down slightly throughout the day on Tuesday. The healthcare sector witnessed some volatility after the release of the Republican plan to replace Obamacare and shares of Snap Inc. fell another 11% just days after its highly-anticipated IPO.
Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices
by Parth Panchal
A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.
Why Is Merck (MRK) Up 3.7% Since the Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 FDA Decisions to Watch Out for in Mar 2017
by Arpita Dutt
Companies like Merck (MRK) are awaiting key FDA decisions this month.
What's in Store for Immune Design (IMDZ) in Q4 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is scheduled to report fourth-quarter 2016 results after the market closes on Mar 7.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.
M&As, Pipeline Catalysts to Drive Pharma Sector
by Arpita Dutt
The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.
Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.
Pharma Industry Outlook - February/March 2017
by Arpita Dutt
The sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5.1% while the NASDAQ Biotechnology Index is up 7.3%.
Bristol Myers' Future Unsure as Carl Icahn Takes Stake
by Joseph Lu
Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?
Can Carl Icahn Save Bristol Myers Squibb?
by Joseph Lu
Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson
The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, PNC Financial, Express Scripts, VeriSign and Martin Marietta
What's Driving Lilly's (LLY) Shares after 2016 Decline?
by Zacks Equity Research
After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.
Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
by Zacks Equity Research
Incyte Corporation (INCY) reported fourth-quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents.
Dow 30 Stock Roundup: Coca-Cola, Disney, Visa Beat on Earnings
by Swarup Gupta
The Dow endured another volatile week as it bobbed and weaved around record highs.
Agilent (A) Announces Expanded Use of Diagnostic Assay (revised)
by Zacks Equity Research
Agilent Technologies (A) recently announced the expanded use of its diagnostic assay, Dako PD-L1 IHC 22C3 pharmDx.
The Zacks Analyst Blog Highlights: Apple, Exxon Mobil, Merck, Pfizer and Intel
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Exxon Mobil, Merck, Pfizer and Intel